Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Unknown Primary × pertuzumab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 58 Neoplasms 8 HER2-positive Breast Cancer 8 Neoplasm Metastasis 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Salivary Gland Neoplasms 2 Prostatic Neoplasms 2 Pathologic Complete Response 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Inflammatory Breast Neoplasms 2 Hematologic Neoplasms 2 HER2-positive Early Breast Cancer 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Urinary Bladder Neoplasms 1 Solid Tumors 1 Solid Cancer 1 Skin Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Rectal Neoplasms 1 Patient Preference 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1

Interventions

pembrolizumab 2 atezolizumab 2 zenocutuzumab 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 entrectinib 1 cobimetinib 1 alectinib 1 Whole Genome Sequencing 1 Vemurafenib 1 Transurethral Resection of Prostate 1 Specimen Handling 1 Sequence Analysis, RNA 1 Radiosurgery 1 Paclitaxel 1 Magnetic Resonance Spectroscopy 1 HhAntag691 1 Genetic Testing 1 Genetic Profile 1 Gemcitabine 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Erlotinib Hydrochloride 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡